1354220-34-0 Usage
Description
5-Bromo-1-(2-methoxyethyl)-1H-indazole is a chemical compound that belongs to the class of indazole derivatives. It is a brominated derivative of 1-(2-methoxyethyl)-1H-indazole, and its molecular formula is C10H12BrN2O.
Uses
Used in Medical and Pharmaceutical Research:
5-Bromo-1-(2methoxyethyl)-1H-indazole is used as a precursor in the synthesis of various bioactive molecules and pharmaceutical drugs. It plays a crucial role in the development of new medications and therapies.
Used in Neurological and Psychiatric Disorders Treatment:
5-Bromo-1-(2methoxyethyl)-1H-indazole is used as a potential therapeutic agent for the treatment of neurological and psychiatric disorders. Its specific effects and mechanisms of action are still under investigation.
Used in the Development of New Psychoactive Substances:
5-Bromo-1-(2-methoxyethyl)-1H-indazole may have applications in the development of new psychoactive substances and designer drugs. However, its recreational use is illegal and strongly discouraged due to its potential health hazards and legal repercussions.
Check Digit Verification of cas no
The CAS Registry Mumber 1354220-34-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,5,4,2,2 and 0 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1354220-34:
(9*1)+(8*3)+(7*5)+(6*4)+(5*2)+(4*2)+(3*0)+(2*3)+(1*4)=120
120 % 10 = 0
So 1354220-34-0 is a valid CAS Registry Number.
1354220-34-0Relevant articles and documents
NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF
-
Paragraph 0770; 0771; 0773, (2018/09/08)
An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. Th e present invention provides a nicotinamide derivative represented by the follo wing formula (I) (wherein R 1 represents a halogen atom; R 2 represents a C 1-12 alkyl group, a C 2-12 alkenyl group, a C 2-12 alkynyl group, a C 3-8 cycloalkyl g roup, an aryl group, an ar-C 1-6 alkyl group or a heterocyclic group, each opti onally having at least one substituent; R 3 represents an aryl group or a hetero cyclic group each optionally having at least one substituent; and R 4 and R 5 e ach independently represent a hydrogen atom; and R 2 and R 4 may form a cyc lic amino group optionally having at least one substituent together with the ni trogen atom to which they bind) or a salt thereof, and a pharmaceutical comp osition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.
